As CEA affects tumor cell biology and its microenvironment, we hypothesized that CEA serum levels might predict the response to anti-VEGF treatment in mCRC exerted by the VEGF-targeting humanized mAb bevacizumab. The gene discussed is CEACAM5; the disease is neoplasm.